Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2 Terminated Gynecologic Oncology Group National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.

Timeline

Start: 2000-02
Primary completion: 2004-01
Completion: —

Publications

Results Miller DS, Blessing JA, Lentz SS, McMeekin DS. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Cancer. 2003 Oct 15;98(8):1664-9. doi: 10.1002/cncr.11690.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topotecan	Small molecule	2 mg/m2	Intravenous

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Summary

Timeline

Publications

Drugs

Indications